Cybin, Inc. (HELP)
12.37
-1.65
(-11.77%)
USD |
NASDAQ |
Sep 18, 16:00
12.70
+0.33
(+2.67%)
After-Hours: 07:43
Cybin Debt to Equity Ratio : 0.00 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.2078 |
| June 30, 2025 | 0.2932 |
| March 31, 2025 | 0.00 |
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.0005 |
| June 30, 2024 | 0.0008 |
| March 31, 2024 | 0.001 |
| December 31, 2023 | 0.003 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| Date | Value |
|---|---|
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.002 |
| July 31, 2019 | 0.00 |
| April 30, 2019 | 0.00 |
| January 31, 2019 | 0.00 |
| October 31, 2018 | 0.00 |
| July 31, 2018 | 0.00 |
| April 30, 2018 | 0.00 |
| January 31, 2018 | 0.00 |
| October 31, 2017 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Atai Beckley, Inc. | 0.0107 |
| Clearmind Medicine, Inc. | 0.1389 |
| InMed Pharmaceuticals, Inc. | 0.00 |
| NervGen Pharma Corp. | 0.00 |
| Milestone Pharmaceuticals, Inc. | 7.785 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 259.66M |
| Total Liabilities (Quarterly) | 17.57M |
| Shareholders Equity (Quarterly) | 242.09M |
| Current Ratio | 10.97 |